

FEB 21 2003

PATENT & TRADEMARK OFFICE

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1631
Examiner Name	Carolyn L. Smith
Attorney Docket Number	G-142US05REG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S	R1	Database GENESEQP, Accession No. AAR99844; "Human natural killer cell, cell surface mol. NKG7", February 11, 1997 (first entry).	
	R2	TURMAN, et al., "Characterization of a novel gene (NKG7) on human chromosome 19 that is expressed in natural killer cells and T cells", <i>Hum. Immunol.</i> (1993), 36:34-40.	
↓	R3	AUSTIN, et al., "Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+CTLs as determined by phenotypic analysis", <i>J. Cutan Pathol.</i> (1998), 25:79-88.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		

RECEIVED
FEB 25 2003
TECH CENTER 1600/2900

Examiner Signature

Date Considered

4/3/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

JAN 28 2003

TECH CENTER 1600/2000

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/978,418
				Filing Date	October 15, 2001
				First Named Inventor	Stephane Bejanin
				Art Unit	1645 - 1631
				Examiner Name	unknown Smith
Sheet	1	of	9	Attorney Docket Number	G-142US05REG

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
CS	U1	US-4,902,505	02/20/1990	Pardridge et al.	
	U2	US-4,987,084	01/22/1991	Tedder et al.	
	U3	US-5,229,494	01/20/1993	Evans et al.	
	U4	US-5,445,942	08/29/1995	Rabin et al.	
	U5	US-5,595,721	01/21/1997	Kaminski et al.	
	U6	US-5,599,400	02/04/1997	Mao et al.	
	U7	US-5,641,670	06/24/1997	Treco et al.	
	U8	US-5,693,496	12/02/1997	Alves et al.	
	U9	US-5,714,459	02/03/1998	O'Brien et al.	
	U10	US-5,762,926	06/09/1998	Gage et al.	
✓	U11	US-5,840,688	11/24/1998	Tso	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
CS	F1	WO 00/55632 A1	09/21/2000	Women's and Children's Hospital	
	F2	WO 01/51618 A2	07/19/2001	Agy Therapeutics, Inc.	
	F3	WO 99/02171 A1	01/21/1999	Texas Heart Institute	
	F4	WO 99/24565 A1	05/20/1999	Gorcynski	
✓	F5	WO 99/38963 A1	08/05/1999	Genesense Technologies, Inc.	

Examiner Signature	<i>Carly S</i>	Date Considered	4/3/03
--------------------	----------------	-----------------	--------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional) ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible ⁶ Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FAXES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231

JAN 27 2003



PTO-SB-08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Art Unit	1645 1631
Examiner Name	Unknown S.m.r.
Attorney Docket Number	G-142US05REG

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CS	U12	US-5,932,536	08/03/1999	Wright et al.	
	U13	US-5,948,756	09/07/1999	Barenholz et al.	
	U14	US-5,952,034	09/14/1999	Buchanan et al.	
	U15	US-5,989,545	11/23/1999	Foster et al.	
	U16	US-6,004,554	12/21/1999	Thorpe et al.	
	U17	US-6,027,935	02/22/2000	Purchio et al.	
	U18	US-6,074,844	06/13/2000	Hillman et al.	
	U19	US-6,090,631	07/18/2000	Catterall et al.	
	U20	US-6,099,857	08/08/2000	Gross	
	U21	US-6,110,747	08/29/2000	Blaschuk et al.	
	U22	US-6,113,951	09/05/2000	Buchanan et al.	
	U23	US-6,117,454	09/12/2000	Kreuter et al.	
	U24	US-6,153,192	11/28/2000	Kopetzki et al.	
	U25	US-6,169,074	01/02/2001	Montal et al.	
	U26	US-6,180,602	01/30/2001	Kato et al.	
↓	U27	US-6,190,723	02/20/2001	Buchanan et al.	

RECEIVED

JAN 28 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CS	F6	WO 98/56818 A1	12/17/1998	Genetics Institute, Inc.	T+
↓	F7	WO 99/06548 A2	02/11/1999	Dumas Milne Edwards et al.	
↓	F8	WO 98/14581 A1	04/09/1998	Schering Corporation	

Examiner Signature	<i>Cathy S.</i>	Date Considered	4/3/03
--------------------	-----------------	-----------------	--------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

JAN 27 2003



PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10-31-2002 GMB 0051-0051
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Art Unit	1645-1631
Examiner Name	unknown S.m.rh
Attorney Docket Number	G-142US05REG

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
CS	U28	US-6,191,154	02/20/2001	Landreth et al.	RECEIVED
↓	U29	US-6,197,940	03/06/2001	Klinefelter	JAN 28 2001
↓	U30	US-6,268,487	07/31/2001	Kutzko et al.	TECH CENTER 1600

RECEIVED

JAN 28 2005

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

4 / 3 / 03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PNULETT

JAN 28 2003

TECH CENTER 1600/2900

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1645 1631
Examiner Name	unknown Smith
Attorney Docket Number	G-142US05REG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	R1	ALBERTIN, G. et al., "Cerebellin stimulates the secretory activity of the rat adrenal gland: in vitro and in vivo studies", <i>Neuropeptides</i> (2000), 34:7-11; INIST CNRS	
	R2	BIBER, K. et al., "Ischemia-Induced Neuronal Expression of the Microglia Attracting Chemokine Secondary Lymphoid-Tissue Chemokine (SLC)", <i>GLIA</i> (2001), 34:121-133; INIST CNRS	
	R3	BRAUN, S. et al., "The CC Chemokine CK β /ELC/Exodus 3 Mediates Tumor Rejection of Murine Breast Cancer Cells Through NK Cells", <i>J. Immunol</i> (2000), 164:4025-31; The American Association of Immunologists	
	R4	BREM, H. et al. "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", <i>J. Neurosurg.</i> (1991), 74:441-446; INIST CNRS	
	R5	BRONSON, R. et al., "Sperm antibodies: their role in infertility", <i>Fertil and Steril</i> (1984), 42:171-83; The American Fertility Society	
	R6	BUNN Jr., P. et al., "Imaging of T-Cell Lymphoma by Radiolabelled Monoclonal Antibody", <i>Lancet</i> (1984), 2:1219-21	
	R7	CELLA, M. et al., "A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing", <i>J. Exp. Med.</i> (1997), 185(10):1743-1751; The Rockefeller University Press	
	R8	CHEE, M. et al., "Accessing Genetic Information with High-Density DNA Arrays", <i>Science</i> (1996), 274:610-614	
	R9	DIALYNAS, D. et al., "Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice", <i>Blood</i> (2001), 97(10):3218-25; The American Society of Hematology	
	R10	DIEU-NOSJEAN, M.-C., et al., "Regulation of the dendritic cell trafficking: a process that involves the participation of selective chemokines", <i>J. Leukoc. Biol.</i> (1999); 66:252-62; INIST CNRS	
	R11	GOSLING, J. et al., "Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK", <i>J. Immunol.</i> (2000), 164:2851-6; The American Association of Immunologists	
	R12	GUNN, M. et al., "A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes", <i>Proc. Natl. Acad. Sci. USA</i> (1998), 95:258-263	
↓	R13	GUNN, M. et al., "Mice Lacking Expression of Secondary Lymphoid Organ Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization", <i>J. Exp. Med.</i> (1999), 189(3):451-460	

Examiner Signature

Date Considered

1/3/03

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

JAN 27 2003



RECEIVED

JAN 28 2003

PTO-SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1500/2000

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1045 1631
Examiner Name	unknown S.M.R.
Attorney Docket Number	G-142US05REG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	R14	HIRAIWA, M. et al., "Binding and transport of gangliosides by prosaposin", <i>Proc. Natl. Acad. Sci. USA</i> (1992), 89:11254-11258	
	R15	HJELMSTRÖM, P. et al., "Lymphoid Tissue Homing Chemokines Are Expressed in Chronic Inflammation", <i>American Journal of Pathology</i> (2000), 156(4):1133-8	
	R16	KANEDA, Y. et al., "Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver", <i>Science</i> (1989), 243:375-8	
	R17	KENNEDY, J.H. et al., "Protein-Protein Coupling Reactions and the Applications of Protein Conjugates", <i>Clin. Chim. Acta</i> (1976), 70:1-31; Elsevier Scientific Publishing Company, Amsterdam, Holland	
	R18	KIM, C. et al., "SLC/Exodus2/6Ckine/TCA4 induces chemotaxis of hemopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation", <i>J. Leukoc. Biol.</i> (1999), 66:455-61	
	R19	KIRK, C. et al., "T Cell-dependent Antitumor Immunity Mediated by Secondary Lymphoid Tissue Chemokine: Augmentation of Dendritic Cell-based Immunotherapy", <i>Cancer Research</i> (1999), 61:2062-70	
	R20	LOECHEL, F. et al., "Human ADAM 12 (Meltrin α) Is an Active Metalloprotease", <i>J. Biol. Chem.</i> (1998), 273:16993-7; The American Society for Biochemistry and Molecular Biology, Inc.	
	R21	LOEFFEN, J. et al., "The human NADH:ubiquinone oxidoreductase NDUFS5 (15kDa) subunit: cDNA cloning, chromosomal localization, tissue distribution and the absence of mutations in isolated complex I-deficient patients", <i>J. Inher. Metab. Dis.</i> (1999), 22:19-28; SSIEM and Kluwer Academic Publishers, Holland	
	R22	MACHENS, H.-G. et al., "Bioartificial Skin", <i>Cells Tissues Organs</i> (2000), 167:88-94; INIST CNRS	
	R23	MARG, A. et al., "Neurotractin, A Novel Neurite Outgrowth-promoting Ig-like Protein that Interacts with CEPU-1 and LAMP", <i>J. Cell Biol.</i> (1999), 145:865-876; The Rockefeller University Press	
	R24	MEDLEY, Q., et al., "Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition", <i>Proc. Natl. Acad. Sci. USA</i> (1996), 93:685-689	
	R25	MELTON, R., et al., "Antibody-Enzyme Conjugates for Cancer Therapy", <i>J. Natl. Cancer Inst.</i> (1996) 88(3/4):153-65; INIST CNRS	

Examiner Signature

Date Considered


4/3/03

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

JAN 27 2003



RECEIVED

JAN 28 2001

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031



TECH CENTER 1600/2000

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1645-1631
Examiner Name	UNKNOWN S.m.r
Attorney Docket Number	G-142US05REG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. [†]	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	R26	MIYACHI, K. et al., "Autoantibody to a Nuclear Antigen in Proliferating Cells", <i>J. Immunol.</i> (1978), 121(6):2228-34; The Williams & Wilkins Co.	
	R27	MORIMOTO, S. et al., "Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases", <i>Proc. Natl. Acad. Sci. USA</i> (1990), 87:3493-3497	
	R28	MULLIGAN, R. "The Basic Science of Gene Therapy", <i>Science</i> (1993), 260:926-32	
	R29	MURPHY, P. et al., "International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors", <i>Pharmacological Reviews</i> (2000), 52(1):145-176	
	R30	NAGIRA, M. et al., "Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13", <i>J. Biol. Chem.</i> (1997), 272(31):19518-24	
	R31	NAGIRA, M. et al., "Enhanced HIV-1 Replication by Chemokines Constitutively Expressed in Secondary Lymphoid Tissues", <i>Virology</i> (1999), 264:422-426, INIST CNRS	
	R32	NOMURA, T. et al., "Enhancement of Anti-Tumor Immunity by Tumor Cells Transfected with the Secondary Lymphoid Tissue Chemokine EBI-1-Ligand Chemokine and Stromal Cell-Derived Factor-1 α Chemokine Genes", <i>Int. J. Cancer</i> (2001), 91:597-606; INIST CNRS	
	R33	PATEL, D. et al., "Chemokines Have Diverse Abilities to Form Solid Phase Gradients", <i>Clinical Immunology</i> (2001), 99(1):43-52; Academic Press	
	R34	RAMSDEN, C.A. et al., "A new disorder of hyaluronan metabolism associated with generalized folding and thickening of the skin", <i>J. Pediatr.</i> (2000), 136(1):62-68	
	R35	RAO, C.N. et al., "Prokaryotic Expression, Purification, and Reconstitution of Biological Activities (Antiprotease, Antitumor, and Heparin-Binding) for Tissue Factor Pathway Inhibitor-2", <i>Biochem. Biophys. Res. Commun.</i> (2000), 276:1286-94; Academic Press	
	R36	REAPE, T. et al., "Expression and Cellular Localization of the CC Chemokines PARC and ELC in Human Atherosclerotic Plaques", <i>Am. J. Pathol.</i> (1999), 81:1-40; American Society for Investigative Pathology	
	R37	SATOH, F. et al., "Cerebellin and cerebellin mRNA in the human brain, adrenal glands and the tumor tissues of adrenal tumour, ganglioneuroblastoma and neuroblastoma", <i>J. Endocrinol.</i> (1997), 154:27-34; Journal of Endocrinology, Ltd., Great Britain	
↓	R38	SCHUURS, A.H.W.M. et al., "Enzyme-Immunoassay", <i>Clin. Chim. Acta</i> (1977), 81:1-40; Elsevier/North-Holland Biomedical Press	

Examiner Signature

Date Considered

4/3/03

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

[†] Applicant's unique citation designation number (optional) [‡] Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JAN 27 2003

JAN 28 2003

PTO/SB-08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1645 1631
Examiner Name	Unknown Smit
Attorney Docket Number	G-142US05REG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	R39	SHARMA, S. et al., "Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo", <i>J. Immunol.</i> (1979), 164:4558-63; The American Association of Immunologists	
	R40	SIMPSON, D.W., et al., "A Rapid, Inexpensive and Easily Quantified Assay for Phagocytosis and Microbicidal Activity of Macrophages and Neutrophils", <i>J. Immunol. Methods</i> (1979), 29:221-226; Elsevier/North-Holland Biomedical Press	
	R41	SWANSON, M. et al., "IFN-γ Production by Th1 Cells Generated from Naive CD4 ⁺ T Cells Exposed to Norepinephrine", <i>J. Immunol.</i> (2001), 166:232-240; The American Association of Immunologists	
	R42	ULMER, J. et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein", <i>Science</i> (1993), 259:1745-9	
	R43	URADE, Y. et al., "Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain", <i>Proc. Natl. Acad. Sci. USA</i> (1991), 88:1069-1073	
	R44	WIKSTRAND, C., et al., "Monoclonal antibody therapy of human gliomas: Current status and future approaches", <i>Cancer Metastasis Rev.</i> (1999), 18:451-64; Kluwer Academic Press, Holland	
	R45	WOLFSBERG, T., et al., "ADAMs in Fertilization and Development", <i>Development Biology</i> (1996), 180:389-401; Academic Press, Inc.	
	R46	YOSHIDA, H., et al., "Identification of the cis-Acting Endoplasmic Reticulum Stress Response Element Responsible for Transcriptional Induction of Mammalian Glucose-regulated Proteins", <i>J. Biol. Chem.</i> (1998), 273:7118-22; The American Society for Biochemistry and Molecular Biology, Inc.	
	R47	Accession No. AAF36777, Database GENBANK, Colonna, M. et al., <i>Eur. J. Immunol.</i> (2000), 30(2):697-704	
	R50	Accession No. AAG45834, Database GENBANK, Nakano, H. et al., <i>J. Immunol.</i> (2001), 166(1):361-369	
	R51	Accession No. AB035356, Database GENPEPT, "Homo sapiens mRNA for neurexin I-alpha protein, complete cds., December 2, 1999	
	R52	Accession No. AF020352, Database GENPEPT, "Homo sapiens NADH:ubiquinone oxidoreductase 15 kDa IP subunit mRNA, nuclear gene encoding mitochondrial protein, complete cds; subunit of Mitochondrial Complex I., May 12, 1999	
	R53	Accession No. CAA50710, Database GENPEPT, Larsen, F. et al., <i>Hum. Mol. Genet.</i> (1993), 2(10):1589-95	

Examiner Signature

Finley SR

Date Considered

7/3/05

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JAN 28 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

8

of

9

Complete if Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1645-1631
Examiner Name	unknown S-n, RL
Attorney Docket Number	G-142US05REG



TECH CENTER 1600/2000

+

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
CS	R54	Accession No. O00585, Database SWISSPROT, Hromas, R. et al., <i>J. Immunol.</i> (1997), 159:2554-2558
	R55	Accession No. O09006, Database SWISSPROT, Hromas, R. et al., <i>J. Immunol.</i> (1997), 159:2554-2558
	R56	Accession No. O43506, Database SWISSPROT, Hooft van Huijsduijnen, R., <i>Gene</i> (1998), 206:273-282
	R57	Accession No. O75926, Database SWISSPROT, Liu, B., <i>Proc. Natl. Acad. Sci. U.S.A.</i> (1998), 95:10626-10631
	R58	Accession No. P01011, Database SWISSPROT, Chandra, T. et al., <i>Biochemistry</i> (1983), 22:5055-5061
	R59	Accession No. P02760, Database SWISSPROT, Vetr, H. et al., <i>Biol. Chem. Hoppe-Seyler</i> (1990), 371:1185-1196
	R60	Accession No. P07602, Database SWISSPROT, Rorman, E.G. et al., <i>Genomics</i> (1989), 5:486-492
	R61	Accession No. P09110, Database SWISSPROT, Bout, A. et al., <i>Nucleic Acids Res.</i> (1988), 16:10369-10369
	R62	Accession No. P11049, Database SWISSPROT, Classon, B.J. et al., <i>J. Exp. Med.</i> (1989), 169:1497-1502
	R63	Accession No. P12004, Database SWISSPROT, Almendral, J.M., <i>Proc. Natl. Acad. Sci. U.S.A.</i> (1987), 84:1575-1579
	R64	Accession No. P12004, Database GENPEPT, Almendral, J.M. et al., <i>Proc. Natl. Acad. Sci. USA</i> (1987), 84(6):1575-1579
	R65	Accession No. P19827, Database GENPEPT, Bost, F. et al., <i>Eur. J. Biochem.</i> (1992), 218(2):283-291
↓	R66	Accession No. P31607, Database GENPEPT, Rouault, J. et al., <i>EMBO J.</i> (1992), 11(4):1663-1670

Examiner Signature	<i>Paul S</i>	Date Considered	4/3/03
--------------------	---------------	-----------------	--------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

JAN 27 2003
PATENT & TRADEMARK OFFICE

RECEIVED

JAN 28 2003

PTO-SB-08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

+

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9

of

9

Complete If Known

Application Number	09/978,418
Filing Date	October 15, 2001
First Named Inventor	Stephane Bejanin
Group Art Unit	1645 1631
Examiner Name	Unknown S. Smith

Attorney Docket Number G-142US05REG

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CS	R68	Accession No. U42068, Database GENPEPT, "Human liver endoplasmic reticulum P58 mRNA, complete cds; protein disulfide isomerase isoform", January 5, 1996	
	R69	Accession No. U82979, Database GENPEPT, Human immunoglobulin-like3 mRNA, complete cds; ILT3; member of the immunoglobulin-superfamily, June 13, 1997	
	R70	Accession No. P41217, Database SWISSPROT, McCaughan, G.W. et al., <i>Immunogenetics</i> (1987), 25(5):329-335	
	R71	Accession No. P48307, Database SWISSPROT, Miyagi, Y. et al., <i>J. Biochem</i> , 116(5):939-942 (1994)	
	R72	Accession No. Q13449, Database SWISSPROT, Pimenta, A.F. et al., <i>Gene</i> (1996), 170(2):189-195	
	R73	Accession No. Q16617, Database SWISSPROT, Turman, M.A. et al., <i>Hum. Immunol.</i> (1993), 36(1):34-40	
↓	R74	Accession No. Q9Y531, Database SPTREMBL, Peck, A., Submitted (JUN-99) to the EMBL/GenBank/DDBJ databases	1999

Examiner Signature	<i>Linda S.</i>	Date Considered	4/3/03
--------------------	-----------------	-----------------	--------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents Washington, DC 20231.